The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and competitors. 

Do you know why China-based companies traded on US exchanges are coming under pressure, what’s next for genetic medicine groups, and which new product launches have the largest commercial potential? Get the answers to these and other pressing questions in this new article pack from Evaluate Vantage. 
 

.

WHAT'S IN THE PACK?

AACR 2022 – the first biopharma catalysts emerge
Another strike for biotech: China
Amgen hold-up gives Mirati a vital lifeline
Looking beyond Roche's Tigit bombshell
What now for low-cost PD-(L)1 competition?
And many more
Thumbnail
Thumbnail